ANIXA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.23 USD | +8.39% |
|
+3.53% | -16.75% |
| 04-18 | Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board | CI |
| 03-12 | Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Valuation
| Fiscal Period: October | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 78.2 | 49.01 | 142.9 | 171.7 | 98.18 | 103 | - |
| Enterprise Value (EV) 1 | 78.2 | 49.01 | 142.9 | 171.7 | 98.18 | 103 | 103 |
| P/E ratio | -6.56 x | -4.58 x | -10.6 x | -12.4 x | -9.88 x | -7.34 x | -7.18 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 313 x | - | 279 x | - | 468 x | - | - |
| EV / Revenue | 313 x | - | 279 x | - | 468 x | - | - |
| EV / EBITDA | -15,275,041 x | -8,445,737 x | - | - | - | - | - |
| EV / FCF | -15,904,822 x | - | - | -12,863,760 x | - | - | - |
| FCF Yield | -0% | - | - | -0% | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,207 | 23,789 | 29,950 | 30,662 | 31,070 | 31,900 | - |
| Reference price 2 | 3.870 | 2.060 | 4.770 | 5.600 | 3.160 | 3.230 | 3.230 |
| Announcement Date | 09/01/20 | 07/01/21 | 04/01/22 | 04/01/23 | 16/01/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: October | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.25 | - | 0.5125 | - | 0.21 | - | - |
| EBITDA | -5.12 | -5.802 | - | - | - | - | - |
| EBIT 1 | -11.89 | -9.978 | -13.14 | -13.88 | -11.01 | -14.56 | -15 |
| Operating Margin | -4,756% | - | -2,563.06% | - | -5,243.33% | - | - |
| Earnings before Tax (EBT) 1 | -11.82 | -10.09 | -13.13 | -13.77 | -9.93 | -14.24 | -15 |
| Net income 1 | -11.65 | -10.02 | -12.95 | -13.6 | -9.811 | -14.2 | -15 |
| Net margin | -4,658.82% | - | -2,527.69% | - | -4,671.9% | - | - |
| EPS 2 | -0.5900 | -0.4500 | -0.4500 | -0.4500 | -0.3200 | -0.4400 | -0.4500 |
| Free Cash Flow | -4.917 | - | - | -13.35 | - | - | - |
| FCF margin | -1,966.75% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 09/01/20 | 07/01/21 | 04/01/22 | 04/01/23 | 16/01/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: October | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.21 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.077 | - | -3.589 | -2.797 | -3.609 | - | -2.56 | -2.844 | -3.051 | -3.609 | -3.65 | -3.65 | -3.65 | - | - |
| Operating Margin | - | - | - | - | - | - | -1,219.05% | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -4.071 | - | -3.588 | -2.775 | -3.529 | - | -2.307 | -2.548 | -2.721 | -3.29 | -3.65 | -3.65 | -3.65 | - | - |
| Net income 1 | -4.013 | - | -3.544 | -2.746 | -3.476 | - | -2.288 | -2.511 | -2.69 | -3.255 | -3.65 | -3.65 | -3.65 | - | - |
| Net margin | - | - | - | - | - | - | -1,089.52% | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1300 | -0.1300 | -0.1200 | -0.0900 | -0.1200 | -0.0800 | -0.0700 | -0.0800 | -0.0900 | -0.1000 | -0.1100 | -0.1100 | -0.1100 | -0.1100 | -0.1100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 04/01/22 | 11/03/22 | 10/06/22 | 09/09/22 | 04/01/23 | 17/03/23 | 14/06/23 | 06/09/23 | 16/01/24 | 12/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: October | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -4.92 | - | - | -13.3 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 09/01/20 | 07/01/21 | 04/01/22 | 04/01/23 | 16/01/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.23
USD
Average target price
12
USD
Spread / Average Target
+271.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.75% | 103M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ANIX Stock
- Financials Anixa Biosciences, Inc.
